About 6 results found for searched term "CDK9-IN-27" (0.171 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41441 | CDK9-IN-27 | CDK |
| CDK9-IN-27 is a CDK9 inhibitor (IC50s: 0.424 μM). | ||
| M2911 | Riviciclib hydrochloride (P276-00) | CDK |
| Riviciclib hydrochloride | ||
| Riviciclib hydrochloride (P276-00) is an effective CDK inhibitor, inhibiting CDK9-CyclinT1, CDK4-cyclin D1, CDK1-Cyclinb with IC50 values of 20 nM, 63 nM, respectively. 79 nM. Riviciclib hydrochloride (P276-00) has anti-tumor activity against Cisplatin resistant cells. | ||
| M5328 | LDC000067 | CDK |
| LDC067 | ||
| LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7. | ||
| M20705 | AS2863619 | CDK |
| AS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells. | ||
| M27698 | ABC1183 | GSK-3 |
| ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities. | ||
| M28917 | CDK8/19-IN-1 | CDK |
| CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
